{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-020833","form_type":"8-K","ticker":"PYXS","cik":"0001782223","company_name":"Pyxis Oncology, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.540866+00:00","generated_at":"2026-06-15T04:30:01.325343+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Pyxis Oncology Q1 net loss $19.2M; cash $150.8M; ODD for PYX-201 in pancreatic cancer","bullets":["Net loss of $19.2M ($0.54 per share) vs $31.4M ($0.97) in Q1 2022; R&D expenses $11.9M, G&A $9.1M.","Cash, equivalents, restricted cash and short-term investments $150.8M, no debt; runway into 1H 2025.","FDA granted Orphan Drug Designation for PYX-201 in pancreatic cancer; Phase 1 trial dosing underway.","Phase 1 trial of PYX-106 dosing expected to begin Q2 2023; preliminary data from both trials late 2023 to early 2024.","One-time $8M payment to Pfizer in Q1 for FACT platform license expansion."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-020833","json":"https://secwatch.observer/filing/0000950170-23-020833.json","markdown":"https://secwatch.observer/filing/0000950170-23-020833.md","text":"https://secwatch.observer/filing/0000950170-23-020833.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782223/000095017023020833/0000950170-23-020833-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782223/000095017023020833/pyxs-20230511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:30:01.325343+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"19926b7a44b1057862ff7a5651f5679832845abd","claim":"Pyxis Oncology, Inc. reported the quarter ended March 31, 2023 results: net income Net loss was $19.2 million, or $0.54 per common share, for the three months ended March 31, 2023, EPS $0.54 per common share.","evidence_excerpt":"Net loss was $19.2 million, or $0.54 per common share, for the three months ended March 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782223/000095017023020833/0000950170-23-020833-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Net income","value":"Net loss was $19.2 million, or $0.54 per common share, for the three months ended March 31, 2023"},{"label":"EPS","value":"$0.54 per common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}